Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Blood (2024) 144 (10): 1083–1092.

https://doi.org/10.1182/blood.2024023962

Published: 2024

Includes: Supplemental data

Journal Articles

Architecture and Early Construction of a Multi-Modal Oncology Registry for Follicular Lymphoma

Mitchell R Smith, Julie Dodds, Hetal Shah, Zoe Drymoussi, David Kennard, Steven Labkoff

Blood (2022) 140 (Supplement 1): 5228–5229.

https://doi.org/10.1182/blood-2022-170156

Published: 2022

Journal Articles

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Blood (2022) 140 (Supplement 1): 186–188.

https://doi.org/10.1182/blood-2022-170381

Published: 2022

Journal Articles

C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition

Fengdong Cheng, MD, Yuan Ren, PhD, Jie Chen, PhD, Zi Wang, B.S., Tao Li, MD, Kieron Dunleavy, MD, Jianqing Lin, MD, James Bradner, MD, Mitchell R. Smith, MDPhD, Bijal D. Shah, MD, Eduardo Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2018) 132 (Supplement 1): 777.

https://doi.org/10.1182/blood-2018-99-116865

Published: 2018

Journal Articles

Parametric Modeling of "Chemotherapy-Free" Regimens in CLL

Mitchell R. Smith, MD PhD, Robert Weiss, PhD

Blood (2018) 132 (Supplement 1): 5555.

https://doi.org/10.1182/blood-2018-99-119782

Published: 2018

Journal Articles

Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment

Jie Chen, PhD, Fengdong Cheng, MD, Michael Wang, Bachelor of Science, Eva Sahakian, PhD, John J. Powers, BS, Javier Pinilla Ibarz, MD, Mitchell R. Smith, MDPhD, Eduardo Sotomayor, MD

Blood (2018) 132 (Supplement 1): 1105.

https://doi.org/10.1182/blood-2018-99-117007

Published: 2018

Journal Articles

A Novel Role for Histone Deacetylase 10 (HDAC10) in the Regulation of PD-L1 Expression and Immune Tolerance Mediated By Antigen Presenting Cells (APCs)

Michael Wang, Bachelor of Science, Fengdong Cheng, MD, Jie Chen, PhD, Yixuan Li, PhD, Alejandro Villagra, PhD, Mitchell R. Smith, MD PhD, Edward Seto, PhD, Eduardo Martin Sotomayor, MD

Blood (2017) 130 (Supplement 1): 3561.

https://doi.org/10.1182/blood.V130.Suppl_1.3561.3561

Published: 2017

Journal Articles

Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia

Jeffrey P. Sharman, MD, Kathryn S. Kolibaba, MD, Jose Azar, MD, Rama Balaraman, MD, Roger M. Lyons, MD, Mitchell R. Smith, MD PhD, Esteban Abella-Dominicis, MD, Wei Ye, PhD, Wen Shi, MD PhD, Thomas Giever, DO, Andres Forero-Torres, MD

Blood (2017) 130 (Supplement 1): 832.

https://doi.org/10.1182/blood.V130.Suppl_1.832.832

Published: 2017

Journal Articles

Marked Re-Expansion of Chimeric Antigen Receptor (CAR) T Cells and Tumor Regression Following Nivolumab Treatment in a Patient Treated with Axicabtagene Ciloleucel (axi-cel; KTE-C19) for Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Brian T. Hill, MD PhD, Zachary J. Roberts, MD PhD, John M. Rossi, MS, Mitchell R. Smith, MD PhD

Blood (2017) 130 (Supplement 1): 2825.

https://doi.org/10.1182/blood.V130.Suppl_1.2825.2825

Published: 2017

Journal Articles

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib

Allison M. Winter, Daniel J. Landsburg, Anthony R. Mato, Krista Isaac, Francisco J. Hernandez-Ilizaliturri, Nishitha Reddy, Stephen Smith, Mazyar Shadman, Mitchell R. Smith, Paolo Caimi, Deepa Jagadeesh, Brian T. Hill

Blood (2017) 130 (14): 1676–1679.

https://doi.org/10.1182/blood-2017-05-786988

Published: 2017

Journal Articles

A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib

Allison Marie Winter, MD, Daniel J. Landsburg, MD, Francisco J. Hernandez-Ilizaliturri, MD, Nishitha Reddy, MD MSCI, MBBS, Stephen Smith, MD, Mazyar Shadman, Paolo Caimi, MD, Deepa Jagadeesh, MD MPH, Mitchell R. Smith, Brian T. Hill, MD PhD

Blood (2016) 128 (22): 1115.

https://doi.org/10.1182/blood.V128.22.1115.1115

Published: 2016

Journal Articles

Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway

Jeffrey P. Sharman, Andrei R. Shustov, Mitchell R. Smith, Christopher T. Hagenstad, Kathryn S. Kolibaba, Esteban Abella-Dominicis, Danjie Zhang, Siddhartha Mitra, Christopher A. Yasenchak, Farrukh T. Awan

Blood (2016) 128 (22): 3225.

https://doi.org/10.1182/blood.V128.22.3225.3225

Published: 2016

Journal Articles

Response-Adapted Therapy for Newly Diagnosed Myeloma

Frederic J. Reu, MD, Tomas Radivoyevitch, PhD, Jason Valent, MD, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Debbie Hastings, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Janice Reed, RN, Mary Ann Karam, RN, Matt Kalaycio, MD FACP, Hien K. Liu, MD, Christy Samaras, DO, Brian J. Bolwell, MD, Mitchell R. Smith

Blood (2016) 128 (22): 3606.

https://doi.org/10.1182/blood.V128.22.3606.3606

Published: 2016

Journal Articles

IPI, Comorbidity Index, Hospitalization for Treatment-Related Adverse Events Are Predictors for Outcome in Elderly Diffuse Large B Cell Lymphoma Patients

Caner Saygin, MD, Xuefei Jia, MS, Brian T. Hill, MD PhD, Robert M. Dean, MD, Bhumika Patel, MD, Brad Pohlman, MD, Mitchell R. Smith, Deepa Jagadeesh, MD MPH

Blood (2016) 128 (22): 1860.

https://doi.org/10.1182/blood.V128.22.1860.1860

Published: 2016

Journal Articles

Once Weekly Subcutaneous Bortezomib, Cyclophosphamide, and Dexamethasone As Induction Therapy for All AL Amyloidosis

Hashim Abbas, Lisa A. Rybicki, MS, Frederic J. Reu, MD, Christy Samaras, DO, Mitchell R. Smith, Debbie Hastings, Jason Valent, MD

Blood (2016) 128 (22): 5813.

https://doi.org/10.1182/blood.V128.22.5813.5813

Published: 2016

Journal Articles

Ibrutinib: a force with a dark side?

Mitchell R. Smith

Blood (2016) 127 (12): 1523–1524.

https://doi.org/10.1182/blood-2016-02-694877

Published: 2016

Journal Articles

The Role of Post- Treatment Imaging in Detection of Relapsed Disease in Classical Hodgkin Lymphoma: The Cleveland Clinic Experience

Nikolaos Papadantonakis, MD PhD, Basel Rouphail, MD MBA, Jia Xuefei, Robert M. Dean, MD, Brian T. Hill, MD PhD, Brad Pohlman, MD, Mitchell R. Smith, MD PhD, Deepa Jagadeesh, MD MPH

Blood (2015) 126 (23): 5006.

https://doi.org/10.1182/blood.V126.23.5006.5006

Published: 2015

Journal Articles

Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma

Blood (2015) 126 (23): 3961.

https://doi.org/10.1182/blood.V126.23.3961.3961

Published: 2015

Journal Articles

Response Adapted Induction Therapy for Multiple Myeloma

Jason Valent, MD, Christy Samaras, DO, Debbie Hastings, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Brian J. Bolwell, MD, Janice Reed, RN, Mary Ann Karam, RN, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Mitchell R. Smith, MD PhD, Hien K. Liu, MD, Frederic J Reu

Blood (2015) 126 (23): 3327.

https://doi.org/10.1182/blood.V126.23.3327.3327

Published: 2015

Journal Articles

Standard Duration of Varicella Zoster Virus Prophylaxis May be Inadequate to Prevent Viral Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Front-Line Bendamustine Plus Rituximab

Joshua M. Allen, MD, Lisa A. Rybicki, MS, Paolo F. Caimi, MD, Deepa Jagadeesh, MD MPH, Robert M. Dean, MD, Brad Pohlman, MD, Mitchell R. Smith, MD PhD, Matt Kalaycio, MD, Brian T. Hill, MD PhD

Blood (2015) 126 (23): 4167.

https://doi.org/10.1182/blood.V126.23.4167.4167

Published: 2015

NARROW

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Architecture and Early Construction of a Multi-Modal Oncology Registry for Follicular Lymphoma

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition

Parametric Modeling of "Chemotherapy-Free" Regimens in CLL

Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment

A Novel Role for Histone Deacetylase 10 (HDAC10) in the Regulation of PD-L1 Expression and Immune Tolerance Mediated By Antigen Presenting Cells (APCs)

Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia

Marked Re-Expansion of Chimeric Antigen Receptor (CAR) T Cells and Tumor Regression Following Nivolumab Treatment in a Patient Treated with Axicabtagene Ciloleucel (axi-cel; KTE-C19) for Refractory Diffuse Large B Cell Lymphoma (DLBCL)

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib

A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib

Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway

Response-Adapted Therapy for Newly Diagnosed Myeloma

IPI, Comorbidity Index, Hospitalization for Treatment-Related Adverse Events Are Predictors for Outcome in Elderly Diffuse Large B Cell Lymphoma Patients

Once Weekly Subcutaneous Bortezomib, Cyclophosphamide, and Dexamethasone As Induction Therapy for All AL Amyloidosis

Ibrutinib: a force with a dark side?

The Role of Post- Treatment Imaging in Detection of Relapsed Disease in Classical Hodgkin Lymphoma: The Cleveland Clinic Experience

Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma

Response Adapted Induction Therapy for Multiple Myeloma

Standard Duration of Varicella Zoster Virus Prophylaxis May be Inadequate to Prevent Viral Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Front-Line Bendamustine Plus Rituximab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only